PRECIGEN, INC. Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share
PRECIGEN, INC. (PGEN) reported Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share of -$0.40 per share for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-01.
Discontinued › Income Statement › Net Income
us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare · last filed 2021-03-01
- PRECIGEN, INC. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic and diluted share for the quarter ending 2020-09-30 was $0.00.
- PRECIGEN, INC. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic and diluted share for the quarter ending 2020-06-30 was $0.00.
- PRECIGEN, INC. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic and diluted share for the quarter ending 2020-03-31 was -$0.16.
- PRECIGEN, INC. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic and diluted share for the quarter ending 2019-09-30 was -$0.03.
- PRECIGEN, INC. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic and diluted share for fiscal 2020 was -$0.40.
- PRECIGEN, INC. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic and diluted share for fiscal 2019 was -$1.00.
- PRECIGEN, INC. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic and diluted share for fiscal 2018 was -$1.03.
- PRECIGEN, INC. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic and diluted share for fiscal 2017 was -$0.39.
| Period end | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share 3 month | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share 6 month | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share 9 month | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share 12 month | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share 12 month as first filed |
|---|---|---|---|---|---|
| 2020-12-31 | -$0.40 10-K · filed 2021-03-01 | ||||
| 2020-09-30 | $0.00 10-Q · filed 2020-11-09 | -$0.16 10-Q · filed 2020-11-09 | |||
| 2020-06-30 | $0.00 10-Q · filed 2020-08-10 | -$0.16 10-Q · filed 2020-08-10 | |||
| 2020-03-31 | -$0.16 10-Q · filed 2020-05-11 | ||||
| 2019-12-31 | -$1.00 10-K · filed 2021-03-01 | -$0.75 10-K · filed 2020-03-02 | |||
| 2019-09-30 | -$0.03 10-Q · filed 2020-11-09 | -$0.14 10-Q · filed 2020-11-09 | |||
| 2019-06-30 | -$0.04 10-Q · filed 2020-08-10 | -$0.10 10-Q · filed 2020-08-10 | |||
| 2019-03-31 | -$0.06 10-Q · filed 2020-05-11 | ||||
| 2018-12-31 | -$1.03 10-K · filed 2021-03-01 | -$0.77 10-K · filed 2020-03-02 | |||
| 2017-12-31 | -$0.39 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |